Logo image
Back
Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness
Journal article   Open access   Peer reviewed

Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

K.D. Harrington, Y.Y. Lim, D. Ames, J. Hassenstab, S.M. Laws, R.N. Martins, S. Rainey‐Smith, J. Robertson, C.C. Rowe, O. Salvado, …
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol.8(1), pp.156-164
2017
DOI: https://doi.org/10.1016/j.dadm.2017.05.006
pdf
systemic illness.pdfDownloadView
Published (Version of Record) Open Access
url
Free to Read *No subscription requiredView

Abstract

Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

Details

Metrics

41 File views/ downloads
26 Record Views
Logo image